Inflammatory bowel disease (IBD) has been associated with an increased risk of nonmelanoma skin cancer, particularly among patients treated with thiopurines.
It is unclear whether IBD affects risk for melanoma.
Dr Edward Loftus and colleagues from Minnesota, USA performed a systematic review and meta-analysis of cohort studies to determine the risk of melanoma in patients with IBD.
The team conducted a systematic search of bibliographic databases through 2013.
Cohort studies reporting incident melanoma after IBD diagnosis and an estimate of incidence rate ratio or standardized incidence rate were included in the analysis.
Pooled relative risk (RR) estimates with 95% confidence intervals (CIs) were calculated using the random-effects model.
The researchers evaluated 12 studies, comprising a total of 172,837 patients with IBD.
|IBD was associated with a 37% increase in risk of melanoma|
|Clinical Gastroenterology & Hepatology|
The team identified 179 cases of melanoma that were reported from 1940 to 2009.
The pooled crude incidence rate of melanoma in patients with IBD was almost28 cases per 100,000 person-years.
Overall, IBD was associated with a 37% increase in risk of melanoma.
The team observed that the risk was increased among patients with Crohn’s disease, and ulcerative colitis.
The risk of melanoma was higher in studies performed before introduction of biologic therapies, but not in studies performed after 1998.
Dr Loftus' team concludes, "Based on a meta-analysis, IBD has been associated with an increased risk of melanoma, independent of the use of biologic therapy."
"Patients diagnosed with IBD should be counseled on their risk for melanoma."